Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2527308 | Clinical Therapeutics | 2012 | 26 Pages |
Abstract
In this study with eligible adult Korean patients who had mild-to-moderate hypertension, the reduction of siDBP after 12 weeks of treatment with fimasartan 60/120 mg was noninferior to that of losartan 50/100 mg. By post hoc comparison, between-group differences in siDBP were significant in favor of fimasartan, suggesting superiority to losartan. There was no statistically significant difference in tolerability between the groups. This efficacy and tolerability were maintained throughout the additional 12-week extension study. ClinicalTrials.gov identifier: NCT00922480.
Related Topics
Health Sciences
Medicine and Dentistry
Medicine and Dentistry (General)
Authors
Sang Eun MD, Yong-Jin MD, Hae-Young MD, Han-Mo MD, Chang-Gyu MD, Jae-Joong MD, Soon-Kil MD, Moo-Yong MD, Byung-Hee MD, PhD, Investigators Investigators,